{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T22:05:10Z","timestamp":1767909910132,"version":"3.49.0"},"reference-count":25,"publisher":"Japanese Society of Internal Medicine","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2017]]},"DOI":"10.2169\/internalmedicine.9096-17","type":"journal-article","created":{"date-parts":[[2017,10,10]],"date-time":"2017-10-10T22:13:25Z","timestamp":1507673605000},"page":"3347-3351","source":"Crossref","is-referenced-by-count":8,"title":["Multiple Myeloma Presenting with Autoimmune Autonomic Ganglionopathy"],"prefix":"10.2169","volume":"56","author":[{"given":"Yoshiki","family":"Nakae","sequence":"first","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Hyuga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Fukunaga","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Tabata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitomo","family":"Maesako","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization Nagasaki Kawatana Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinari","family":"Nakane","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kumamoto University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Arima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Goldstein DS, McRae A, Holmes C, Dalakas MC. Autoimmune autonomic failure in a patient with myeloma-associated Shy-Drager syndrome. Clin Auton Res 6: 17-21, 1996.","DOI":"10.1007\/BF02291401"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Klein CM, Vernino S, Lennon VA, et al. The spectrum of autoimmune autonomic neuropathies. Ann Neurol 53: 752-758, 2003.","DOI":"10.1002\/ana.10556"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 343: 847-855, 2000.","DOI":"10.1056\/NEJM200009213431204"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Chinn JS, Schuffler MD. Paraneoplastic visceral neuropathy as a cause of severe gastrointestinal motor dysfunction. Gastroenterology 95: 1279-1286, 1988.","DOI":"10.1016\/0016-5085(88)90362-9"},{"key":"5","unstructured":"5. Lee HR, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 96: 373-379, 2001."},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Miwa A. [Lymphoid malignancies: progress in diagnosis and treatment. Topics: III. Diagnosis and treatment; 3. Diagnosis, laboratory examination, and treatment for multiple myeloma]. Nihon Naika Gakkai Zasshi 100: 1850-1874, 2011 (in Japanese).","DOI":"10.2169\/naika.100.1850"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kaneko K, Seta K, Soma J, et al. Gamma 1-heavy chain deposition disease accompanied by IgG kappa in serum, urine, and bone marrow. CEN Case Rep 3: 44-48, 2014.","DOI":"10.1007\/s13730-013-0083-0"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Nakane S, Higuchi O, Koga M, et al. Clinical features of autoimmune autonomic ganglionopathy and the detection of subunit-specific autoantibodies to the ganglionic acetylcholine receptor in Japanese patients. PLoS One 10: e0118312, 2015.","DOI":"10.1371\/journal.pone.0118312"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 20: 1467-1473, 2006.","DOI":"10.1038\/sj.leu.2404284"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Leone C, Federico V, La Cesa S, et al. An observational study assessing peripheral neuropathy related to multiple myeloma. Neurol Sci 37: 1141-1143, 2016.","DOI":"10.1007\/s10072-016-2542-9"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003.","DOI":"10.1056\/NEJMoa030288"},{"key":"12","unstructured":"12. Rajkumar SV. Thalidomide in multiple myeloma. Oncology (Williston Park) 14 (12 Suppl 13): 11-16, 2000."},{"key":"13","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","volume":"108","author":"PG Richardson","year":"2006","unstructured":"13. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 108: 3458-3464, 2006.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Richardson PG, Siegel D, Baz R, et al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121: 1961-1967, 2013.","DOI":"10.1182\/blood-2012-08-450742"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gupta A, Harris S, Vernino S, Naina HV. Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy. Clin Auton Res 25: 255-258, 2015.","DOI":"10.1007\/s10286-015-0299-5"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Nakane S. [Autoimmune autonomic ganglionopathy]. Rinsho Shinkeigaku 53: 1071-1073, 2013 (in Japanese, Abstract in English).","DOI":"10.5692\/clinicalneurol.53.1071"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Iodice V, Kimpinski K, Vernino S, et al. Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy. Neurology 72: 2002-2008, 2009.","DOI":"10.1212\/WNL.0b013e3181a92b52"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Alexander T, Sarfert R, Klotsche J, et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74: 1474-1478, 2015.","DOI":"10.1136\/annrheumdis-2014-206016"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Cort\u00e9s-Hern\u00e1ndez J, \u00c1vila G, Vilardell-Tarr\u00e9s M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 14: R265, 2012.","DOI":"10.1186\/ar4111"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Shah A, Albrecht J, Bonilla-Martinez Z, et al. Lenalidomide for the treatment of resistant discoid lupus erythematosus. Arch Dermatol 145: 303-306, 2009.","DOI":"10.1001\/archdermatol.2009.30"},{"key":"21","unstructured":"21. Braunstein I, Goodman NG, Rosenbach M, et al. Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare. J Am Acad Dermatol 66: 571-582, 2012."},{"key":"22","unstructured":"22. Green J, Upjohn E, McCormack C, Zeldis J, Prince HM. Successful treatment of Beh\u00e7et&apos;s disease with lenalidomide. Br J Dermatol 158: 197-198, 2008."},{"key":"23","unstructured":"23. Dubbeld P, van der Heul C, Hillen HF. Effect of high-dose dexamethasone in prednisone-resistant autoimmune thrombocytopenic purpura (ITP). Neth J Med 39: 6-10, 1991."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Godeau B, Bierling P, Oksenhendler E, Castaigne S, Deconinck E, Wechsler B. High-dose dexamethasone therapy for resistant autoimmune thrombocytopenic purpura. Am J Hematol 51: 334, 1996.","DOI":"10.1002\/1096-8652(199604)51:4<334::AID-AJH2830510409>3.0.CO;2-V"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Zhan Y, Zou S, Hua F, et al. High-dose dexamethasone modulates serum cytokine profile in patients with primary immune thrombocytopenia. Immunol Lett 160: 33-38, 2014.","DOI":"10.1016\/j.imlet.2014.03.002"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/24\/56_9096-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T12:40:25Z","timestamp":1570192825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/56\/24\/56_9096-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":25,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9096-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}